Tokimus Biotech is an American medical technology and biotech solutions company dedicated to improving healthcare access through reliable diagnostics, high-quality medical devices, and innovative biomedical products.
Founded by Patrick L Riggs a Havard university Graduate and experts in medicine, biotech, and global supply chain logistics, Tokimus Biotech was created to solve a critical challenge: the gap between global medical innovation and the communities that need it most. Many regions urban, rural, and Indigenous face barriers to accessing trusted medical equipment, diagnostic tools, and preventive healthcare technologies. We are here to close that gap.
To deliver affordable, innovative, and regulatory-approved medical technology that empowers healthcare systems, enhances diagnosis and treatment, and supports healthier communities across the America’s, United Kingdom, Europe, Asia and Africa
A future where healthcare technology is equitable, accessible, and optimized, enabling every clinic, hospital, and community to receive the tools they need to protect and improve human health.
for more details.
Pat was born in Italy and has worked in the import/export business dealing with energy, food and restaurant products, oil field equipment and supplies since 2004. His primary business has been as a finance consultant and strategy advisor to middle market companies in re-capitalization for growth programs. He likewise provides guidance for early stage and small public companies seeking growth capital. As Import Manager for an international trading company, he developed long term relationships with several key Asian trading partners; an experience which is serving Tokimus Biotech very well as it established its relationships with Asian suppliers. Pat attended University of North Dakota in 1990 and completed independent study program receiving university credits at Harvard Business School in 2019.
Jason was born and raised in Taiwan and received his degree in accounting form Aletheia University in Taiwan. He completed his MBA at the University of Houston and is a licensed CPA in the United States. Due to his continued ties to Taiwan, China and Asia, Jason provides valuable insights into the business culture of Southeast Asia as well as providing valuable contacts there. In his career, he has been instrumental in financing both US and foreign entrepreneurial companies. Aside from managing the financial matters of Tokimus Biotech, Jason makes valuable business contacts for the company in Asia.
has served as the President and CEO/Founder of THE 5Ps, LLC, a health care, education and leadership consulting firm,since August 2009. He served in the U.S. Army for more than 35 years before retiring inJune 2009, and he was the Deputy Director and Program Executive Officer of TRICAREManagement Activity, Office of the Assistant Secretary of Defense (Health Affairs), inWashington, D.C., from December 2005 to June 2009.General Granger is board certified by the American Association for Physician Leadership,American College of Healthcare Executives, American Board of Medical Quality and theAmerican Board of Internal Medicine. He is also a National Association of CorporateDirectors (NACD) Certified Director. General Granger has extensive experience in health care management and operations,including health policy, planning, budgeting and execution related to the health program foruniformed service members around the globe through his tenure with TRICARE. Gen Granger has unique leadership and policy experience through his 35-year career with theU.S. Army.
Mr. Jarbath has decades of experience in clinic operations in research and successfully advised and completed publishing of research paper of Tokimus development project to prestigious medical journal Frontiers in Molecular Biosciences
RESOLVE is a 43-year-old independent, nonprofit organization (501c3) providing collaborative problem-solving including designing and leading solutions-focused programs, offering mediation and facilitation expertise, and supporting programs development and impact enterprise formation that address environmental, health, social, and economic issues. RESOLVE had partnered with Tokimus during Pandemic to facilitate the required donations and funds flows plus comply with international regulatory matters to follow GAVI/ COVAX vaccine protocols.
Dr. Rosenblatt has more than 30 years of clinical and biomedical research and development experience in multiple settings, including academia, biotech, startups, and clinical practice, and he has published over 80 papers and book chapters on cancer and neuronal biology, biomarker development, and clinical genomics and proteomics. Currently, he is President and Medical Director of Consultative Genomics, PLLC, a molecular pathology group specializing in Genomic and Proteomic clinical testing as applied to chronic disease, population health management, and personalized medicine.
Eric Seok is a Seoul-based medical product and master export distributor for Asia andhas represented Tokimus as agent for several key COVID-19 related products via his TNF Bio as exporter. Mr. Seok spent two decades in businessin and out of Hyundai Group, educated in New Zealand, and USA.
We collaborate with internationally recognized, ISO-certified, and FDA-cleared manufacturers to bring cutting-edge biotech and medical equipment to North America.
Every product meets strict North American regulatory and performance requirements.
Our dual expertise in biotechnology and global logistics ensures efficient, compliant, and transparent delivery no matter the scale.
We work with public health organizations, Indigenous communities, clinics, and nonprofit partners to ensure essential healthcare technology reaches the areas that need it most.
Technology matters but impact matters more. Everything we deliver is aligned with improving health outcomes.
Tokimus Biotech provides comprehensive medical technology solutions, supporting healthcare providers, governments, clinics, and distributors as biomedical developers seeking to builda trusted portfolio of diagnostics, devices, and biotech innovations.